-
1Academic Journal
Authors: Ambroci, R., Sorici, G., Cîvîrjic, I., Diaconu, N., Grosu, A.A.
Source: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 81 (1) 160-166
Subject Terms: cheie: P-selectină, embolie pulmonara, tromboembolism venos, biomarkeri, P-селектин, тромбоэмболия легочной артерии, венозная тромбоэмболия, биомаркеры, P-selectin, pulmonary embolism, venous thromboembolism, biomarkers
File Description: application/pdf
Relation: https://ibn.idsi.md/vizualizare_articol/237894; urn:issn:18570011
-
2Academic Journal
Authors: V. O. Bitsadze, J. Kh. Khizroeva, E. Grandone, R. I. Gabidullina, M. V. Tretyakova, N. A. Makatsariya, N. R. Gashimova, K. N. Grigoreva, A. V. Vorobev, A. V. Lazarchuk, M. M. Muravyova, A. G. Krendeleva, T. E. Polyakova, M. S. Zainulina, D. L. Kapanadze, F. E. Yagubova, J.-C. Gris, I. Elalamy, G. Gerotziafas, P. Van Dreden, A. D. Makatsariya, В. О. Бицадзе, Д. Х. Хизроева, Э. Грандоне, Р. И. Габидуллина, М. В. Третьякова, Н. А. Макацария, Н. Р. Гашимова, К. Н. Григорьева, А. В. Воробьев, А. В. Лазарчук, М. М. Муравьёва, А. Г. Кренделева, Т. Е. Полякова, М. С. Зайнулина, Д. Л. Капанадзе, Ф. Э. Ягубова, Ж.-К. Гри, И. Элалами, Г. Геротзиафас, П. Ван Дреден, А. Д. Макацария
Contributors: The authors declare no funding, Авторы заявляют об отсутствии финансовой поддержки
Source: Obstetrics, Gynecology and Reproduction; Vol 19, No 3 (2025); 377-388 ; Акушерство, Гинекология и Репродукция; Vol 19, No 3 (2025); 377-388 ; 2500-3194 ; 2313-7347
Subject Terms: риск тромбообразования, IVF, assisted reproductive technologies, ART, ovarian stimulation, thrombosis, ovarian hyperstimulation syndrome, OHSS, thrombophilia, venous thromboembolism, arterial thrombosis, risk factors, thrombosis prevention, thrombogenesis risk, ЭКО, вспомогательные репродуктивные технологии, ВРТ, стимуляция яичников, тромбоз, синдром гиперстимуляции яичников, СГЯ, тромбофилия, венозная тромбоэмболия, артериальный тромбоз, факторы риска, профилактика тромбозов
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2494/1346; Calhaz-Jorge C., De Geyter C.H., Kupka M.S. et al. Survey on ART and IUI: legislation, regulation, funding and registries in European countries: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod Open. 2020;2020(1):hoz044. https://doi.org/10.1093/hropen/hoz044.; European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE); Smeenk J., Wyns C., De Geyter C. et al. ART in Europe, 2019: results generated from European registries by ESHRE. Hum Reprod. 2023;3(12):2321–38. https://doi.org/10.1093/humrep/dead197.; Farquhar C., Marjoribanks J., Brown J. et al. Management of ovarian stimulation for IVF: narrative review of evidence provided for World Health Organization guidance. Reprod Biomed Online. 2017;35(1):3–16. https://doi.org/10.1016/j.rbmo.2017.03.024.; Nelson S.M. Venous thrombosis during assisted reproduction: novel risk reduction strategies. Thromb Res. 2013;131 Suppl 1:S1–3. https://doi.org/10.1016/S0049-3848(13)00023-6.; Grandone E., Villani M. Assisted reproductive technologies and thrombosis. Thromb Res. 2015;135 Suppl 1:S44–5. https://doi.org/10.1016/S0049-3848(15)50441-6.; Kupka M.S., Ferraretti A.P., de Mouzon J. et al.; European IVF-Monitoring Consortium, for the European Society of Human Reproduction and Embryology. Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE†. Hum Reprod. 2014;29(10):2099–113. https://doi.org/10.1093/humrep/deu175.; Sennström M., Rova K., Hellgren M. et al. Thromboembolism and in vitro fertilization – a systematic review. Acta Obstet Gynecol Scand. 2017;96(9):1045–52. https://doi.org/10.1111/aogs.13147.; Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90(5 Supple):S188–93. https://doi.org/10.1016/j.fertnstert.2008.08.034.; Grandone E., Colaizzo D., Vergura P. et al. Age and homocysteine plasma levels are risk factors for thrombotic complications after ovarian stimulation. Hum Reprod. 2004;19(8):1796–9. https://doi.org/10.1093/humrep/deh346.; Henriksson P., Westerlund E., Wallén H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:е8632. https://doi.org/10.1136/bmj.e8632.; Rova K., Passmark H., Lindqvist P.G. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012;97(1):95–100. https://doi.org/10.1016/j.fertnstert.2011.10.038.; Nelson S.M. Prophylaxis of VTE in women – during assisted reproductive techniques. Thromb Res. 2009;123 Suppl 3:S8–S15. https://doi.org/10.1016/S0049-3848(09)70127-6.; Hansen A.T., Kesmodel U.S., Juul S., Hvas A.M. No evidence that assisted reproduction increases the risk of thrombosis: a Danish national cohort study. Hum Reprod. 2012;27(5):1499–503. https://doi.org/10.1093/humrep/des041.; Serour G.I., Aboulghar M., Mansour R. et al. Complications of medically assisted conception in 3,500 cycles. Fertil Steril. 1998;70(4):638–42. https://doi.org/10.1016/s0015-0282(98)00250-7.; Girolami A., Scandellari R., Tezza F. et al. Arterial thrombosis in young women after ovarian stimulation: case report and review of the literature. J Thromb Thrombolysis. 2007;24(2):169–74. https://doi.org/10.1007/s11239-007-0009-9.; Chan W.S. The 'ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009;21(3):207–18. https://doi.org/10.1097/GCO.0b013e328329c2b8.; Yang S., Yuan J., Qin W. et al. The clinical characteristics of acute cerebrovascular accidents resulting from ovarian hyperstimulation syndrome. Eur Neurol. 2017;77(5–6):221–30. https://doi.org/10.1159/000463383.; Filipovic-Pierucci A., Gabet A., Deneux-Tharaux C. et al. Arterial and venous complications after fertility treatment: a French nationwide cohort study. Eur J Obstet Gynecol Reprod Biol. 2019;237:57–63. https://doi.org/10.1016/j.ejogrb.2019.02.034.; Chan W.S, Dixon M.E. The "ART" of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res. 2008;121(6):713–26. https://doi.org/10.1016/j.thromres.2007.05.023.; Villani M., Favuzzi G., Totaro P. et al. Venous thromboembolism in assisted reproductive technologies: comparison between unsuccessful versus successful cycles in an Italian cohort. J Thromb Thrombolysis. 2018;45(2):234–9. https://doi.org/10.1007/s11239-017-1584-z.; Mozes M., Bogokowsky H., Antebi E. et al. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet. 1965;2(7424):1213–5. https://doi.org/10.1016/s0140-6736(65)90636-7.; Kermode A.G., Churchyard A., Carroll W.M. Stroke complicating severe ovarian hyperstimulation syndrome. Aust N Z J Med. 1993;23(2):219–20. https://doi.org/10.1111/j.1445-5994.1993.tb01823.x.; Inbar O.J., Levran D., Mashiach S., Dor J. Ischemic stroke due to induction of ovulation with clomiphene citrate and menotropins without evidence of ovarian hyperstimulation syndrome. Fertil Steril. 1994;62(5):1075–6. https://doi.org/10.1016/s0015-0282(16)57078-2.; Cluroe A.D., Synek B.J. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology. 1995;27(4):344–6. https://doi.org/10.1080/00313029500169273.; Chan W.S., Ginsberg J.S. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the 'ART' behind the clot. J Thromb Haemost. 2006;4(8):673–7. https://doi.org/10.1111/j.1538-7836.2006.02026.x.; Fleming T., Sacks G., Nasser J. Internal jugular vein thrombosis following ovarian hyperstimulation syndrome. Aust N Z J Obstet Gynaecol. 2012;52(1):87–90. https://doi.org/10.1111/j.1479-828X.2011.01392.x.; Salomon O., Schiby G., Heiman Z. et al. Combined jugular and subclavian vein thrombosis following assisted reproductive technology – new observation. Fertil Steril. 2009;92(2):620–5. https://doi.org/10.1016/j.fertnstert.2008.07.1708.; Aboulghar M.A., Mansour R.T., Serour G.I., Amin Y.M. Moderate ovarian hyperstimulation syndrome complicated by deep cerebrovascular thrombosis. Hum Reprod. 1998;13(8):2088–91. https://doi.org/10.1093/humrep/13.8.2088.; Kodama H., Fukuda J., Karube H. et al. Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism. Fertil Steril. 1995;64(6):1207–9. https://doi.org/10.1016/s0015-0282(16)57987-4.; Delvigne A., Demoulin A., Smitz J. et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod. 1993;8(9):1353–60. https://doi.org/10.1093/oxfordjournals.humrep.a138260.; Dulitzky M., Cohen S.B., Inbal A. et al. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertil Steril. 2002;77(3):463–7. https://doi.org/10.1016/s0015-0282(01)03218-6.; Grandone E., Di Micco P.P., Villani M. et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: Data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.; Olausson N., Discacciati A., Nyman A.I. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization with fresh respectively frozen-thawed embryo transfer: nationwide cohort study. J Thromb Haemost. 2020;18(8):1965–73. https://doi.org/10.1111/jth.14840.; Abramov Y., Elchalal U., Schenker J.G. Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril. 1998;70(6):1070–6. https://doi.org/10.1016/s0015-0282(98)00350-1.; Bauersachs R.M., Manolopoulos K., Hoppe I. et al. More on: the 'ART' behind the clot: solving the mystery. J Thromb Haemost. 2007;5(2):438–9.; Richardson M.A., Berg D.T., Calnek D.S. et al. 17beta-estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway. Endocrinology. 2000;141(10):3908–11. https://doi.org/10.1210/endo.141.10.7798.; Rogolino A., Coccia M.E., Fedi S. et al. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Blood Coagul Fibrinolysis. 2003;14(3):277–82. https://doi.org/10.1097/01.mbc.0000061296.28953.d0.; Ricci G., Bogatti P., Fischer-Tamaro L. et al. Factor V Leiden and prothrombin gene G20210A mutation and in vitro fertilization: prospective cohort study. Hum Reprod. 2011;26(11):3068–77. https://doi.org/10.1093/humrep/der261.; Goualou M., Noumegni S., de Moreuil C. et al. Venous thromboembolism associated with assisted reproductive technology: a systematic review and meta-analysis. Thromb Haemost. 2023;123(3):283–94. https://doi.org/10.1055/s-0042-1760255.; Pabinger I., Grafenhofer H., Kaider A. et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005;3(5):949–54. https://doi.org/10.1111/j.1538-7836.2005.01307.x.; Milenkovic J., Milojkovic M., Mitic D. et al. Interaction of thrombophilic SNPs in patients with unexplained infertility-multifactor dimensionality reduction (MDR) model analysis. J Assist Reprod Genet. 2020;37(6):1449–58. https://doi.org/10.1007/s10815-020-01808-4.; Santos T.D.S., Ieque A.L., de Carvalho H.C. et al. Antiphospholipid syndrome and recurrent miscarriage: A systematic review and meta-analysis. J Reprod Immunol. 2017;123:78–87. https://doi.org/10.1016/j.jri.2017.09.007.; El Hasbani G., Khamashta M., Uthman I. Antiphospholipid syndrome and infertility. Lupus. 2020;29(2):105–17. https://doi.org/10.1177/0961203319893763.; Qublan H.S., Eid S.S., Ababneh H.A. et al. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod. 2006;21(10):2694–8. https://doi.org/10.1093/humrep/del203.; Nesbit C., Gunalp C., Zhang J. et al. Longitudinal assessment of coagulation potential before, during, and following an in vitro fertilization cycle. Thromb Res. 2024;238:97–102. https://doi.org/10.1016/j.thromres.2024.04.020.; Azem F., Many A., Ben Ami I. et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod. 2004;19(2):368–70. https://doi.org/10.1093/humrep/deh069.; Hansen A.T., Kesmodel U.S., Juul S., Hvas A.M. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014;29(3):611–7. https://doi.org/10.1093/humrep/det458.; Refsum H., Nurk E., Smith A.D. et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006;136(6 Suppl):1731S–1740S. https://doi.org/10.1093/jn/136.6.1731S.; Fuchs H.E., O'Connell K., Du M. et al. Vitamin B12 supplementation and vitamin B12 blood serum levels: evaluation of effect modification by gender and smoking status. Nutr Cancer. 2022;74(7):2373–83. https://doi.org/10.1080/01635581.2021.2007271.; Bazzano L.A., He J., Muntner P. et al. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003;138(11):891–7. https://doi.org/10.7326/0003-4819-138-11-200306030-00010.; Villani M., Dentali F., Colaizzo D. et al. Pregnancy-related venous thrombosis: comparison between spontaneous and ART conception in an Italian cohort. BMJ Open. 2015;5(10):e008213. https://doi.org/10.1136/bmjopen-2015-008213.; Rosendaal F.R. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82(2):610–9.; Grandone E., Ageno W. The legacy of Edwards and Steptoe and the windy roads of assisted reproduction: where do we stand with venous thromboembolism? Thromb Haemost. 2023;123(3):267–9. https://doi.org/10.1055/a-1996-1341.; Yinon Y., Pauzner R., Dulitzky M. et al. Safety of IVF under anticoagulant therapy in patients at risk for thrombo-embolic events. Reprod Biomed Online. 2006;12(3):354–8. https://doi.org/10.1016/s1472-6483(10)61009-7.; Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–e736S. https://doi.org/10.1378/chest.11-2300.; Grandone E., Piazza G. Thrombophilia, inflammation, and recurrent pregnancy loss: a case-based review. Semin Reprod Med. 2021;39(1–02):62–8. https://doi.org/10.1055/s-0041-1731827.; Sticchi E., Romagnuolo I., Cellai A.P. et al. Fibrinolysis alterations in infertile women during controlled ovarian stimulation: influence of BMI and genetic components. Thromb Res. 2012;130(6):919–24. https://doi.org/10.1016/j.thromres.2012.07.005.; Gurunath S., Vinekar S., Biliangady R. Assisted reproductive techniques in a patient with history of venous thromboembolism: a case report and review of literature. J Hum Reprod Sci. 2018;11(2):193–7. https://doi.org/10.4103/jhrs.JHRS5817.; Westerlund E., Antovic A., Hovatta O. et al. Changes in von Willebrand factor and ADAMTS13 during IVF. Blood Coagul Fibrinolysis. 2011;22(2):127–31. https://doi.org/10.1097/MBC.0b013e32834363ea.; https://www.gynecology.su/jour/article/view/2494
-
3Academic Journal
Authors: A. V. Vorobev, V. O. Bitsadze, J. Kh. Khizroeva, A. G. Solopova, D. M. Mamchich, E. D. Mun, D. V. Blinov, J.-C. Gris, I. Elalamy, G. Gerotziafas, P. Van Dreden, A. D. Makatsariya, А. В. Воробьев, В. О. Бицадзе, Д. Х. Хизроева, А. Г. Солопова, Д. М. Мамчич, Э. Д. Мун, Д. В. Блинов, Ж.-К. Гри, И. Элалами, Г. Геротзиафас, П. Ван Дреден, А. Д. Макацария
Contributors: The authors declare no funding, Авторы заявляют об отсутствии финансовой поддержки
Source: Obstetrics, Gynecology and Reproduction; Vol 19, No 3 (2025); 351-359 ; Акушерство, Гинекология и Репродукция; Vol 19, No 3 (2025); 351-359 ; 2500-3194 ; 2313-7347
Subject Terms: противоопухолевый эффект, АСТ, ovarian cancer, OC, relapse, metastasis, venous thromboembolism, direct oral anticoagulants, thrombin, fibrin matrix, thrombosis, tumor invasion, antitumor effect, АКТ, рак яичников, РЯ, рецидив, метастазирование, венозная тромбоэмболия, прямые оральные антикоагулянты, тромбин, фибриновый матрикс, тромбоз, инвазия опухоли
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2493/1343; Sung H., Ferlay J., Siegel R.L. at al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660; Бредихин Р.А., Ахметзянов Р.В., Хайруллин Р.Н. Расширение возможностей лечения и профилактики венозных тромбоэмболических осложнений у пациентов с онкологическими заболеваниями. Роль пероральных антикоагулянтов. Клиницист. 2022;16(2):17–26. https://doi.org/10.17650/1818-8338-2022-16-2-К667.; Mulder F.I., Horváth-Puhó E., van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–69. https://doi.org/10.1182/blood.2020007338.; Streiff M.B. Thrombosis in the setting of cancer. Hematology Am Soc Hematol Educ Program. 2016;2016(1):196–205. https://doi.org/10.1182/asheducation-2016.1.196.; Guo J., Gao Y., Gong Z. et al. Plasma D-dimer level correlates with age, metastasis, recurrence, tumor-node-metastasis classification (TNM), and treatment of non-small-cell lung cancer (NSCLC) patients. Biomed Res Int. 2021;2021:9623571. https://doi.org/10.1155/2021/9623571.; Hisada Y., Mackman N. Tissue factor and cancer: regulation, tumor growth and metastasis. Semin Thromb Hemost. 2019;45(4):385–95. https://doi.org/10.1055/s-0039-1687894.; Zhao B., Wu M., Hu Z. et al. A novel oncotherapy strategy: direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer. Br J Pharmacol. 2022;179(22):5056–73. https://doi.org/10.1111/bph.15384.; Hisada Y., Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499–506. https://doi.org/10.1182/blood-2017-03-743211.; Слуханчук Е.В., Бицадзе В.О., Хизроева Д.Х. и др. Тромбоциты, тромбовоспаление и онкологический процесс. Акушерство, Гинекология и Репродукция. 2021;15(6):755–76. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.274.; Stone R.L., Nick A.M., McNeish I.A. et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–8. https://doi.org/10.1056/NEJMoa1110352.; Zhou L., Zhang Z., Tian Y. et al. The critical role of platelet in cancer progression and metastasis. Eur J Med Res. 2023;28(1):385. https://doi.org/10.1186/s40001-023-01342-w.; Miyazaki M., Nakabo A., Nagano Y. et al. Tissue factor-induced fibrinogenesis mediates cancer cell clustering and multiclonal peritoneal metastasis. Cancer Lett. 2023;553:215983. https://doi.org/10.1016/j.canlet.2022.215983.; Cohen A.T., Hamilton M., Mitchell S.A. et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thrombo-embolism: systematic review and network meta-analysis. PLoS One. 2015;10(12):e0144856. https://doi.org/10.1371/journal.pone.0144856.; Farge D., Frere C., Connors J.M. et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–e347. https://doi.org/10.1016/S1470-2045(22)00160-7.; Key N.S., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline Update. J Clin Oncol. 2023;41(16):3063–71. https://doi.org/10.1200/JCO.23.00294.; Kurube I., Ambari E., Iskandar T. et al. Factors associated with recurrence of epithelial ovarian cancer In RSUP Dr. Kariadi Semarang. DIMJ. 2022;3(2):74–80. https://doi.org/10.14710/dimj.v3i2.15448.; Joy J., Kumar J., Kumar S., Arshad M. Clinical profiles and survival outcomes of patients with relapsed ovarian cancer: a single-center study. Cureus. 2024;16(11):e74724. https://doi.org/10.7759/cureus.74724.; Al-Azzawi H.M.A., Hamza S.A., Paolini R. et al. Towards an emerging role for anticoagulants in cancer therapy: a systematic review and meta-analysis. Front Oral Health. 2024;5:1495942. https://doi.org/10.3389/froh.2024.1495942.; Najidh S., Versteeg H.H., Buijs J.T. A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models. Thromb Res. 2020;187:18–27. https://doi.org/10.1016/j.thromres.2019.12.022.; https://www.gynecology.su/jour/article/view/2493
-
4Academic Journal
Authors: E. V. Slukhanchuk, V. O. Bitsadze, A. G. Solopova, J. Kh. Khizroeva, K. N. Grigoreva, N. R. Gashimova, N. A. Makatsariya, D. V. Blinov, V. N. Galkin, A. Yu. Shatilina, E. M. Lyadnova, N. A. Shulga, L. T. Toguzaeva, S. Morkos, J.-C. Gris, I. Elalamy, G. Gerotziafas, A. D. Makatsariya, Е. В. Слуханчук, В. О. Бицадзе, А. Г. Солопова, Д. Х. Хизроева, К. Н. Григорьева, Н. Р. Гашимова, Н. А. Макацария, Д. В. Блинов, В. Н. Галкин, А. Ю. Шатилина, Е. М. Ляднова, Н. А. Шульга, Л. Т. Тогузаева, С. Моркос, Ж.-К. Гри, И. Элалами, Г. Геротзиафас, А. Д. Макацария
Source: Obstetrics, Gynecology and Reproduction; Vol 18, No 6 (2024); 835-846 ; Акушерство, Гинекология и Репродукция; Vol 18, No 6 (2024); 835-846 ; 2500-3194 ; 2313-7347
Subject Terms: ХТ, venous thromboembolism, thrombosis, chemotherapy, СТ, венозная тромбоэмболия, тромбоз, химиотерапия
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2288/1279; Elyamany G., Alzahrani A.M., Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014;8:129-37. https://doi.org/10.4137/cmo.s18991.; Heit J.A., Silverstein M.D., Mohr D.N. et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-15. https://doi.org/10.1001archinte.160.6.809.; Blom J.W., Vanderschoot J., Oostindier M. et al. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3):529-35. https://doi.org/10.1111/j.1538-7836.2006.01804.x.; Khorana A.A., Francis C.W., Culakova E., Lyman G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-9. https://doi.org/10.1002/cncr.21496.; Duggan C., Marriott K., Edwards R., Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol. 2003;21(19):3588-93. https://doi.org/10.1200/JCO.2003.10.111.; Fisher B., Dignam J., Emir B. al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-82. https://doi.org/10.1093/jnci/89.22.1673.; Clahsen P.C., Van de Velde C., Julien J.-P. et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994;12(6):1266-71. https://doi.org/10.1200/JCO.1994.12.6.1266.; Goodnough L.T., Saito H., Manni A. et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. Cancer. 1984;54(7):1264-8. https://doi.org/10.1002/1097-0142(19841001)54:73.0.co;2-r.; Cantwell B., Carmichael J., Ghani S.E., Harris A.L. Thromboses and thromboemboli in patients with lymphoma during cytotoxic chemotherapy. BMJ. 1988;297(6642):179-80. https://doi.org/10.1136/bmj.297.6642.179.; Rickles F.R., Levine M.N. Epidemiology of thrombosis in cancer. Acta Haematol. 2001;106(1-2):6-12. https://doi.org/10.1159/000046583.; Lubiniecki G.M., Berlin J.A., Weinstein R.B., Vaughn D.J. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. Cancer. 2004;101(12):2755-9. https://doi.org/10.1002/cncr.20673.; Kuenen B.C., Rosen L., Smit E.F. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002;20(6):1657-67. https://doi.org/10.1200/JCO.2002.20.6.1657.; Palumbo A., Bertola A., Musto P. et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104(7):1428-33. https://doi.org/10.1002/cncr.21342.; Wang M., Dimopoulos M.A., Chen C. et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112(12):4445-51. https://doi.org/10.1182/blood-2008-02-141614.; Rajkumar S.V., Blood E., Vesole D. et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431-6. https://doi.org/10.1200/JCO.2005.03.0221.; Glasmacher A., Hahn C., Hoffmann F. M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132(5):584-93. https://doi.org/10.1111/j.1365-2141.2005.05914.x.; Lee C.-K., Barlogie B., Munshi N. et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003;21(14):2732-9. https://doi.org/10.1200/JCO.2003.01.055.; Steurer M., Sudmeier I., Stauder R., Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol. 2003;121(1):101-3. https://doi.org/10.1046/j.1365-2141.2003.04252.x.; Palladini G., Russo P., Milani P. et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013;98(3):433-6. https://doi.org/10.3324/haematol.2012.073593.; van Es N., Sturk A., Middeldorp S., Nieuwland R. Effects of cancer on platelets. Semin Oncol. 2014;41(3):311-8. https://doi.org/10.1053/j.seminoncol.2014.04.015.; Thaler J., Pabinger I., Sperr W.R., Ay C. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res. 2014;133(3):303-5. https://doi.org/10.1016/j.thromres.2013.12.029.; Swystun L.L., Mukherjee S., Liaw P.C. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost. 2011;9(11):2313-21. https://doi.org/10.1111/j.1538-7836.2011.04465.x.; Kirwan C.C., Mccollum C.N., McDowell G., Byrne G. Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis. Clin Appl Thromb Hemost. 2015;21(5):420-7. https://doi.org/10.1177/1076029615575071.; Chen L., Deng H., Cui H. et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204-18. https://doi.org/10.18632/oncotarget.23208.; Mo J., Zhang D., Yang R. Expression of P-selectin, VCAM-1, and PSGL-1 in traumatic deep venous thrombosis. Int J Clin Exp Pathol. 2016;9(3):3403-9.; Feng Y., Li X., Xiao J. et al. ADAMTS13: more than a regulator of thrombosis. Int J Hematol. 2016;104(5):534-9. https://doi.org/10.1007/s12185-016-2091-2.; Бицадзе В.О., Слуханчук Е.В., Хизроева Д.Х. и др. Внеклеточные ловушки нейтрофилов (NETs) в патогенезе тромбоза и тромбовоспа-лительных заболеваний. Вестник Российской академии медицинских наук. 2021;76(1):75-85. https://doi.org/10.15690/vramn1395.; Izzedine H., Isnard-Bagnis C., Launay-Vacher V. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21(11):3038-45. https://doi.org/10.1093/ndt/gfl507.; Ohtsu H., Dempsey P.J., Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol. 2006;291(1):C1-C10. https://doi.org/10.1152/ajpcell.00620.2005.; Choi M.K., Hong J.Y., Jang J.H., Lim H.Y. TTP-HUS associated with sunitinib. Cancer Res Treat. 2008;40(4):211-3. https://doi.org/10.4143/crt.2008.40.4.211.; Ojeda-Uribe M., Merieau S., Guillon M. et al. Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate. J Oncol Pharm Pract. 2016;22(2):361-70. https://doi.org/10.1177/1078155214568580.; Biss T., Avery P., Williams M. et al. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children. J Thromb Haemost. 2013;11(2):373-5. https://doi.org/10.1111/jth.12072.; Terrell D., Williams L., Vesely S. et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3(7):1432-6. https://doi.org/10.1111/j.1538-7836.2005.01436.x.; Okano E., Ko S., Kanehiro H. et al. ADAMTS13 activity decreases after hepatectomy, reflecting a postoperative liver dysfunction. Hepatogastroenterology. 2010;57(98):316-20.; Liu L., Choi H., Bernardo A. et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost. 2005;3(11):2536-44. https://doi.org/10.1111/j.1538-7836.2005.01561.x.; Sato N., Tasaki T., Noguchi H. et al.The pathological challenge of establishing a precise diagnosis for pulmonary tumour thrombotic microangiopathy: identification of new diagnostic criteria. Histopathology. 2019;74(6):892-901. https://doi.org/10.1111/his.13813.; Turner N.A., Nolasco L., Ruggeri Z.M., Moake J.L. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood. 2009;114(24):5102-11. https://doi.org/10.1182/blood-2009-07-231597.; Van Es N., Le Gal G., Otten H.-M. et al. Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data. Ann Intern Med. 2017;167(6):410-7. https://doi.org/10.7326/M17-0868.; Lee M., Rodansky E.S., Smith J.K., Rodgers G.M. ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis. Microvas Res. 2012;84(2):109-15. https://doi.org/10.1016/j.mvr.2012.05.004.; Feys H., Liu F., Dong N. et al. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost. 2006;4(5):955-62. https://doi.org/10.1111/j.1538-7836.2006.01833.x.; Kearon C., Akl E.A., Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-52. https://doi.org/10.1016/j.chest.2015.11.026.; Hedrick C.C., Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22(3):173-87. https://doi.org/10.1038/s41577-021-00571-6.; Kan M., Imaoka H., Watanabe K. et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study. Cancer Chemother Pharmacol. 2020;86(2):203-10. https://doi.org/10.1007/s00280-020-04110-3.; Kasi P.M., Grothey A. Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs. 2018;78:737-45. https://doi.org/10.1007/s40265-018-0909-3.; Zhang Y., Guoqiang L., Sun M., Lu X. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment. Cancer Biol Med. 2020;17(1):32—43. https://doi.org/10.20892/j.issn.2095-3941.2019.0372.; Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426—37. https://doi.org/10.1038/nrc3066.; Lee Y.J., Yoon K.-A., Han J.-Y. et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy circulating DNA in prognosis of advanced NSCLC. Clin Cancer Res. 2011;17(15):5179—87. https://doi.org/10.1158/1078-0432.CCR-11-0400.; Слуханчук Е.В., Бицадзе В.О., Солопова А.Г. и др. Маркеры внеклеточных ловушек нейтрофилов у женщин со злокачественными новообразованиями репродуктивной системы, получавших хирургическое лечение и адъювантную терапию. Акушерство, Гинекология и Репродукция. 2023;17(4):420-32. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.432.; Demers M., Wagner D.D. Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013;2(2):e22946. https://doi.org/10.4161/onci.22946.; Holdenrieder S., Stieber P., von Pawel J. et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10(18 Pt 1):5981—7. https://doi.org/10.1158/1078-0432.CCR-04-0625.; Fuchs T.A., Kremer Hovinga J.A., Schatzberg D. et al. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012;120(6):1157-64. https://doi.org/10.1182/blood-2012-02-412197.; Elmoamly S., Mattar M., Yacoub M.F., Afif A. Can biomarkers of coagulation, platelet activation, and inflammation predict venous thromboembolism in patients with haematological malignancies? Acta Haematol. 2019;141(4):245-53. https://doi.org/10.1159/000496914.; Marconi S., Croce M., Chiorino G. et al. A circulating risk score, based on combined expression of exo-miR-130a-3p and fibrinopeptide a, as predictive biomarker of relapse in resectable non-small cell lung cancer patients. Cancers. 2022;14(14):3412. https://doi.org/10.3390/cancers14143412.; Edwards R.L., Klaus M., Matthews E. et al. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 1990;89(1):25-8. https://doi.org/10.1016/0002-9343(90)90093-s.; Zurborn K.H., Gram J., Glander K. et al. Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias. Eur J Haematol. 1991;47(1):55-9.; Stahli B.E., Camici G.G., Steffel J. et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res. 2006;99(2):149-55. https://doi.org/10.1161/01.RES.0000233379.92010.fd.; Adamson I.Y., Bowden D.H. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77(2):185-97.; Bertomeu M., Gallo S., Lauri D. et al. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis. 1990;8(6):511-8. https://doi.org/10.1007/BF00135874.; Sobierajska K., Ciszewski W.M., Sacewicz-Hofman I., Niewiarowska J. Endothelial cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1234:71-86. https://doi.org/10.1007/978-3-030-37184-5_6.; Li C.-X., He Q., Wang Z.-Y. et al. Risk assessment of venous thromboembolism in head and neck cancer patients and its establishment of a prediction model. Head Neck. 2023;45(10):2515-24. https://doi.org/10.1002/hed.27475.; van der Schoot G.G.F., Ormel H.L., Westerink N.-D.L. et al. Physical exercise in patients with testicular cancer treated with bleomycin, etoposide and cisplatin chemotherapy: pulmonary and vascular endothelial function—an exploratory analysis. J Cancer Res Clin Oncol. 2023;149(19):17467-78. https://doi.org/10.1007/s00432-023-05469-5.; Hamza M.S., Mousa S.A. Cancer-associated thrombosis: risk factors, molecular mechanisms, future management. Clin Appl Thromb Hemost. 2020;26:1076029620954282. https://doi.org/10.1177/1076029620954282.; Aklilu A.M., Shirali A.C. Chemotherapy-associated thrombotic microangiopathy. Kidney360. 2023;4(3):409-22. https://doi.org/10.34067/KID.0000000000000061.; Prandoni P., Campello E., editors. Venous thromboembolism in cancer patients undergoing chemotherapy: risk factors and prevention. Semin Thromb Hemost. 2021;47(8):914-9. https://doi.org/10.1055/s-0040-1718927.; Yang V., Gouveia M.J., Santos J. et al. Breast cancer: insights in disease and influence of drug methotrexate. RSC Med Chem. 2020;11(6):646-64. https://doi.org/10.1039/d0md00051e.; Sulimai N.H., Brown J., Lominadze D. Fibrinogen, fibrinogen-like 1 and fibrinogen-like 2 proteins, and their effects. Biomedicines. 2022;10(7):1712. https://doi.org/10.3390/biomedicines10071712.; Fulcher J., Carrier M. Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia-time to reconsider current approaches? Thromb Res. 2020;188:100-2. https://doi.org/10.1016/j.thromres.2020.02.015.; https://www.gynecology.su/jour/article/view/2288
-
5Academic Journal
Authors: N. Yu. Semigolovskii, I. S. Simutis, D. S. Salygina, M. S. Danilov, A. V. Svetlikov, S. N. Semigolovskii, Н. Ю. Семиголовский, И. С. Симутис, Д. С. Салыгина, М. С. Данилов, А. В. Светликов, С. Н. Семиголовский
Source: Meditsinskiy sovet = Medical Council; № 6 (2024); 205-211 ; Медицинский Совет; № 6 (2024); 205-211 ; 2658-5790 ; 2079-701X
Subject Terms: венозная тромбоэмболия, тромбоз глубоких вен, тромбоэмболия легочной артерии, тромболитик, нормотензивные пациенты, deep vein thrombosis, pulmonary embolism, thrombolytic, normotensive patients
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8288/7310; Righini M, Robert-Ebadi H, Le Gal G. Diagnosis of pulmonary embolism. Presse Med. 2015;44(12 Pt 2):e385–391. https://doi.org/10.1016/j.lpm.2015.10.007.; Семиголовский НЮ, Титков ЮС, Гайденко ГВ. Новое в интенсивной терапии тромбоэмболии мелких ветвей легочной артерии. В: Материалы IV съезда анестезиологов и реаниматологов России: тезисы докладов, Москва, июнь 1994 г. М.; 1994. С. 267.; Гайденко ГВ, Лосев НА, Семиголовский НЮ. Способ лечения тромбоэмболии легочной артерии. Патент RU 2224525 C1, 27.02.2004. Режим доступа: https://yandex.ru/patents/doc/RU2224525C1_20040227.; Van Haren FMP, Page C, Laffey JG, Artigas A, Camprubi-Rimblas M, Nunes Q et al. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care. 2020;24(1):454. https://doi.org/10.1186/s13054-020-03148-2.; Van Haren FMP, Laffey JG, Artigas A, Page C, Schultz MJ, Cosgrave D et al. Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studies. Br J Clin Pharmacol. 2022;88(7):3272–3287. https://doi.org/10.1111/bcp.15253.; Bertanha M, Rodrigues LDS, Mellucci Filho PL, Moroz A, Pardini MIMC, Sobreira ML et al. Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: Triple-blind clinical trial. Medicine (Baltimore). 2021;100(51):e28288. https://doi.org/10.1097/MD.0000000000028288.; Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–3069. https://doi.org/10.1093/eurheartj/ehu283.; Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl. 2):S501–518. https://doi.org/10.1161/CIR.0000000000000264.; Wiener RS, Ouellette DR, Diamond E, Fan VS, Maurer JR, Mularski RA et al. An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. Chest. 2014;145(6):1383–1391. https://doi.org/10.1378/chest.14-0670.; Harjola VP, Mebazaa A, Čelutkienė J, Bettex D, Bueno H, Chioncel O et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18(3):226–241. https://doi.org/10.1002/ejhf.478.; Méan M, Tritschler T, Limacher A, Breault S, Rodondi N, Aujesky D, Qanadli SD. Association between computed tomography obstruction index and mortality in elderly patients with acute pulmonary embolism: A prospective validation study. PLoS ONE. 2017;12(6):e0179224. https://doi.org/10.1371/journal.pone.0179224.; Daley MJ, Murthy MS, Peterson EJ. Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem. Ther Adv Drug Saf. 2015;6(2):57–66. https://doi.org/10.1177/2042098615572333.; Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405.; Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402–1411. https://doi.org/10.1056/NEJMoa1302097.; Verstraete M. Third-generation thrombolytic drugs. Am J Med. 2000;109(1):52–58. https://doi.org/10.1016/s0002-9343(00)00380-6.; Gusev EI, Martynov MY, Nikonov AA, Shamalov NA, Semenov MP, Gerasimets EA et al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021;20(9):721–728. https://doi.org/10.1016/S1474-4422(21)00210-6.; Кириенко АИ, Яровая ЕБ, Куценко ВА, Орловский АА, Иванов СВ, Семенов МП и др. Неиммуногенная стафилокиназа в сравнении с алтеплазой у пациентов с массивной ТЭЛА: протокол многоцентрового открытого рандомизированного сравнительного клинического исследования ФОРПЕ. Флебология. 2022;16(2):114–121. https://doi.org/10.17116/flebo202216021114.; Черепанова НА, Муллова ИС, Павлова ТВ, Эрлих АД, Барбараш ОЛ, Бернс СА и др. Тромболитическая терапия в лечении пациентов с тромбоэмболией легочной артерии невысокого риска по данным регистра СИРЕНА. Рациональная фармакотерапия в кардиологии. 2021;17(3):401–407. https://doi.org/10.20996/1819-6446-2021-06-11.; Володюхин МЮ, Хасанова ДР, Тимченко ЛВ, Подшивалов ИА, Телятник ЮА, Демин ТВ и др. Опыт многоцентрового применения препарата Фортелизин при проведении этапной реперфузионной терапии острого ишемического инсульта в каротидной системе. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(6):72–77. https://doi.org/10.17116/jnevro202312306172.; Mican J, Toul M, Bednar D, Damborsky J. Structural Biology and Protein Engineering of Thrombolytics. Comput Struct Biotechnol J. 2019;17:917–938. https://doi.org/10.1016/j.csbj.2019.06.023.
-
6Academic Journal
Authors: T.F. Tatarchuk, Z.M. Dubossarska, V.I. Pyrohova, N.Y. Pedachenko, T.M. Tutchenko, O.О. Yefimenko, N.V. Kosei, Y.O. Dubossarska, K.L. Shatylovych, V.M. Zaporozhan, V.V. Kaminskyi, G.V. Zaichenko, S.A. Dubrov, L.M. Chernukha
Source: REPRODUCTIVE ENDOCRINOLOGY. :9-16
Subject Terms: менопаузальная гормональная терапия, combined hormonal contraceptives, venous thromboembolism, 3. Good health, 03 medical and health sciences, angiotensin-converting enzyme 2 receptors, 0302 clinical medicine, комбинированные гормональные контрацептивы, венозная тромбоэмболия, рецепторы ангиотензинпревращающего фермента 2, незарегистрированные рецептурные биоидентичные гормональные средства, menopausal hormonal therapy, unregistered compounded bioidentical hormonal agents
File Description: application/pdf
-
7Academic Journal
Authors: V. Khryshchanovich
Source: Кардиология в Беларуси. :564-577
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, венозная тромбоэмболия, SARS-CoV-2, venous thromboembolism, COVID-19, тромбопрофилактика, thromboprophylaxis, outcomes, исходы, 3. Good health
-
8Academic Journal
Authors: K. N. Grigoreva, V. O. Bitsadze, J. Kh. Khizroeva, E. V. Slukhanchuk, M. V. Tretyakova, N. A. Makatsariya, J.-Ch. Gris, G. C. Di Renzo, V. I. Tsibizova, D. V. Blinov, A. D. Makatsariya, К. Н. Григорьева, В. О. Бицадзе, Д. Х. Хизроева, Е. В. Слуханчук, М. В. Третьякова, Н. А. Макацария, Ж.-К. А. Гри, Д. К. Ди Ренцо, В. И. Цибизова, Д. В. Блинов, А. Д. Макацария
Source: Obstetrics, Gynecology and Reproduction; Vol 16, No 3 (2022); 306-316 ; Акушерство, Гинекология и Репродукция; Vol 16, No 3 (2022); 306-316 ; 2500-3194 ; 2313-7347
Subject Terms: венозная тромбоэмболия эндотелиальная дисфункция, PE, pregnancy, venous thromboembolism, endothelial dysfunction, ПЭ, беременность
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1361/1025; https://www.gynecology.su/jour/article/view/1361/1026; English F.A., Kenny L.C., McCarthy F.P. Risk factors and effective management of preeclampsia. Integr Blood Press Control. 2015;8:7–12. https://doi.org/10.2147/IBPC.S50641.; Egan K., Kevane B., NíAinle F. Elevated venous thromboembolism risk in preeclampsia: molecular mechanisms and clinical impact. Biochem Soc Trans. 2015;43(4):696–701. https://doi.org/10.1042/BST20140310.; Gris J.-C., Bouvier S., Cochery-Nouvellon É. et al. The role of haemostasis in placenta-mediated complications. Thromb Res. 2019;181 Suppl 1:S10– S14. https://doi.org/10.1016/S0049-3848(19)30359-7.; Ramlakhan K.P., Johnson M.R., Roos-Hesselink J.W. Pregnancy and cardiovascular disease. Nat Rev Cardiol. 2020;17(11):718–31. https://doi.org/10.1038/s41569-020-0390-z.; Matsuo K., Kooshesh S., Dinc M. et al. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol. 2007;24(4):257–66. https://doi.org/10.1055/s-2007-976548.; Pijnenborg R., Vercruysse L., Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006;27(9–10):939– 58. https://doi.org/10.1016/j.placenta.2005.12.006.; Rana S., Lemoine E., Granger J.P., Karumanchi S.A. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–112. https://doi.org/10.1161/CIRCRESAHA.118.313276.; Guerby P., Tasta O., Swiader A. et al. Role of oxidative stress in the dysfunction of the placental endothelial nitric oxide synthase in preeclampsia. Redox Biol. 2021;40:101861. https://doi.org/10.1016/j.redox.2021.101861.; Sánchez-Aranguren L.C., Prada C.E., Riaño-Medina C.E., Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol. 2014;5:372. https://doi.org/10.3389/fphys.2014.00372.; Системные синдромы в акушерско-гинекологической клинике: руководство для врачей. Под ред. А.Д. Макацария. М.: МИА, 2010. 897 с.; Lamarca B. Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia. Minerva Ginecol. 2012;64(4):309–20.; Fakhouri F., Vercel C., Frémeaux-Bacchi V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol. 2012;7(12):2100–6. https://doi.org/10.2215/CJN.13121211.; Wang M., Hao H., Leeper N.J., Zhu L.; Early Career Committee. Thrombotic regulation from the endothelial cell perspectives. Arterioscler Thromb Vasc Biol. 2018;38(6):e90–e95. https://doi.org/10.1161/ATVBAHA.118.310367.; Weissgerber T.L., Garcia-Valencia O., Milic N.M. et al. Early onset preeclampsia is associated with glycocalyx degradation and reduced microvascular perfusion. J Am Heart Assoc. 2019;8(4):e010647. https://doi.org/10.1161/JAHA.118.010647.; Martin F.A., Murphy R.P., Cummins P.M. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol. 2013;304(12):H1585–97. https://doi.org/10.1152/ajpheart.00096.2013.; Turner R.J., Bloemenkamp K.W., Bruijn J.A., Baelde H.J. Loss of thrombomodulin in placental dysfunction in preeclampsia. Arterioscler Thromb Vasc Biol. 2016;36(4):728–35. https://doi.org/10.1161/ATVBAHA.115.306780.; Fraser R., Whitley G.S., Johnstone A.P. et al. Impaired decidual natural killer cell regulation of vascular remodelling in early human pregnancies with high uterine artery resistance. J Pathol. 2012;228(3):322–32. https://doi.org/10.1002/path.4057.; Hayes-Ryan D., Khashan A.S., Hemming K. et al. Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland). BMJ. 2021;374:n1857. https://doi.org/10.1136/bmj.n1857.; Poon L.C., Magee L.A., Verlohren S. et al. A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: compiled by the pregnancy and non-communicable diseases committee of FIGO (the international federation of gynecology and obstetrics). Int J Gynaecol Obstet. 2021;154 Suppl 1:3–31. https://doi.org/10.1002/ijgo.13763.; Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368–80. https://doi.org/10.1200/JCO.2002.10.088.; Levine R.J., Maynard S.E., Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–83. https://doi.org/10.1056/NEJMoa031884.; McKeeman G.C., Ardill J.E., Caldwell C.M. et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004;191(4):1240–6.https://doi.org/10.1016/j.ajog.2004.03.004.; Chaiworapongsa T., Romero R., Espinoza J. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190(6):1541–7; discussion 1547–50. https://doi.org/10.1016/j.ajog.2004.03.043.; Maynard S.E., Min J.Y., Merchan J. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58. https://doi.org/10.1172/JCI17189.; Hu Y., Yan R., Zhang C. et al. HMGB1 from hypoxic trophoblasts promotes endothelial microparticle production and thrombophilia in preeclampsia. Arterioscler Thromb Vasc Biol. 2018;38(6):1381–91.https://doi.org/10.1161/ATVBAHA.118.310940.; Hu Y., Li H., Yan R. et al. Increased neutrophil activation and plasma DNA levels in patients with pre-eclampsia. Thromb Haemost. 2018;118(12):2064–73. https://doi.org/10.1055/s-0038-1675788.; Слуханчук Е.В. NETs и онкологический процесс. Акушерство, Гинекология и Репродукция. 2021;15(1):107–116. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.204.; Jacobsen A.F., Skjeldestad F.E., Sandset P.M. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost. 2008;6(6):905–12. https://doi.org/10.1111/j.1538-7836.2008.02961.x.; Peixoto A.B., Araujo Júnior E., Ribeiro J.U. et al. Evaluation of inflammatory mediators in the deciduas of pregnant women with pre-eclampsia/eclampsia. J Matern Fetal Neonatal Med. 2016;29(1):75–9. https://doi.org/10.3109/14767058.2014.987117.; Regal J.F., Burwick R.M., Fleming S.D. The complement system and preeclampsia. Curr Hypertens Rep. 2017;19(11):87. https://doi.org/10.1007/s11906-017-0784-4.; Sudo M., Yoshita K., Ito Y. et al. Histopathological features of kidney and renal prognosis in patients with preeclampsia. Pregnancy Hypertens. 2021;25:75–80. https://doi.org/10.1016/j.preghy.2021.05.015.; Paré E., Parry S., McElrath T.F. et al. Clinical risk factors for preeclampsia in the 21st century. Obstet Gynecol. 2014;124(4):763–70. https://doi.org/10.1097/AOG.0000000000000451.; Zera C.A., Seely E.W., Wilkins-Haug L.E. et al. The association of body mass index with serum angiogenic markers in normal and abnormal pregnancies. Am J Obstet Gynecol. 2014;211(3):247.e1–7. https://doi.org/10.1016/j.ajog.2014.03.020.; Raia-Barjat T., Edebiri O., Ni Ainle F. Preeclampsia and venous thromboembolism: pathophysiology and potential therapy. Front Cardiovasc Med. 2022;9:856923. https://doi.org/10.3389/fcvm.2022.856923.; Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008;51(4):970–5. https://doi.org/10.1161/HYPERTENSIONAHA.107.107607.; Chunilal S.D., Bates S.M. Venous thromboembolism in pregnancy: diagnosis, management and prevention. Thromb Haemost. 2009;101(3):428–38.; Parunov L.A., Soshitova N.P., Ovanesov M.V. et al. Epidemiology of venous thromboembolism (VTE) associated with pregnancy. Birth Defects Res C Embryo Today. 2015;105(3):167–84. https://doi.org/10.1002/bdrc.21105.; Konstantinides S.V., Meyer G., Becattini C. et al., ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405.; Pregnancy Mortality Surveillance System. Center for Disease Control and Prevention, 2019. Available at: https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortalitysurveillance-system.htm.; Rodger M. Pregnancy and venous thromboembolism: ’TIPPS’ for risk stratification. Hematol Am Soc Hematol Educ Program. 2014;2014(1):387–92. https://doi.org/10.1182/asheducation-2014.1.387.; Liu S., Rouleau J., Joseph K.S. et al. Epidemiology of pregnancyassociated venous thromboembolism: a population-based study in Canada. J Obstet Gynaecol Can. 2009;31(7):611–20. https://doi.org/10.1016/S1701-2163(16)34240-2.; ACOG Practice Bulletin No. 196: Thromboembolism in pregnancy. Obstet Gynecol. 2018;132(1):e1–е17. https://doi.org/10.1097/AOG.0000000000002706.; Bates S.M., Middeldorp S., Rodger M. et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92–128. https://doi.org/10.1007/s11239-015-1309-0.; Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium (Greentop Guideline No 37a). London: RCOG, 2015. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg37a.pdf.; Linnemann B., Bauersachs R., Rott H. et al.; Working Group in Women’s Health of the Society of Thrombosis and Haemostasis. Diagnosis of pregnancy-associated venous thromboembolism – position paper of the Working Group in Women’s Health of the Society of Thrombosis and Haemostasis (GTH). Vasa. 2016;45(2):87–101. https://doi.org/10.1024/0301-1526/a000503.; Sennstrom M., Rova K., Hellgren M. et al. Thromboembolism and in vitro fertilization–a systematic review. Acta Obstet Gynecol Scand. 2017;96(9):1045–52. https://doi.org/10.1111/aogs.13147.; Sultan A.A., West J., Grainge M.J. et al. Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study. BMJ. 2016;355:i6253. https://doi.org/10.1136/bmj.i6253.; Sultan A.A., Tata L.J., West J. et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood. 2013;121(19):3953–61. https://doi.org/10.1182/blood-2012-11-469551.; Osol G., Moore L.G. Maternal uterine vascular remodeling during pregnancy. Microcirculation. 2014;21(1):38–47. https://doi.org/10.1111/micc.12080.; Sultan A.A., West J., Tata L.J. et al. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol. 2012;156(3):366–73. https://doi.org/10.1111/j.1365-2141.2011.08956.x.; Zhou Z.-H., Chen Y., Zhao B.-H. et al. Early postpartum venous thromboembolism: risk factors and predictive index. Clin Appl Thromb Hemost. 2019;25:1076029618818777. https://doi.org/10.1177/1076029618818777.; Sultan A.A., Grainge M.J., West J. et al. Impact of risk factors on the timing of first postpartum venous thromboembolism: a population-based cohort study from England. Blood. 2014;124(18):2872–80. https://doi.org/10.1182/blood-2014-05-572834.; Benschop L., Duvekot J.J., van Lennep R.J.E. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart. 2019;105(16):1273–8. https://doi.org/10.1136/heartjnl-2018-313453.; Thilaganathan B., Kalafat E. Cardiovascular system in preeclampsia and beyond. Hypertension. 2019;73(3):522–31. https://doi.org/10.1161/HYPERTENSIONAHA.118.11191.; Craici I., Wagner S., Garovic V.D. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis. 2008;2(4):249–59. https://doi.org/10.1177/1753944708094227.; van Oostwaard M.F., Langenveld J., Schuit E. et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol. 2015;212(5):624.e1–17. https://doi.org/10.1016/j.ajog.2015.01.009.; Barton J.R., Sibai B.M. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008;112(2 Pt 1):359–72. https://doi.org/10.1097/AOG.0b013e3181801d56.; Mostello D., Kallogjeri D., Tungsiripat R., Leet T. Recurrence of preeclampsia: effects of gestational age at delivery of thefirst pregnancy, body mass index, paternity, and interval between births. Am J Obstet Gynecol. 2008;199(1):55.e1–7. https://doi.org/10.1016/j.ajog.2007.11.058.; van Rijn B.B., Hoeks L.B., Bots M.L. et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol. 2006;195(3):723–8. https://doi.org/10.1016/j.ajog.2006.06.044.; Bramham K., Briley A.L., Seed P. et al. Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study. Am J Obstet Gynecol. 2011;204(6):512.e1–9. https://doi.org/10.1016/j.ajog.2011.02.014.; McDonald S.D., Best C., Lam K. The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort. BJOG. 2009;116(12):1578–84. https://doi.org/10.1111/j.1471-0528.2009.02317.x.; Benschop L., Duvekot J.J., Roeters van Lennep J.E. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart. 2019;105(16):1273–8.; Leon L.J., McCarthy F.P., Direk K. et al. Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records: a CALIBER study. Circulation. 2019;140(13):1050–60. https://doi.org/10.1161/HYPERTENSIONAHA.118.038080.; Alsnes I.V., Vatten L.J., Fraser A. et al. Hypertension in pregnancy and offspring cardiovascular risk in young adulthood: prospective and sibling studies in the HUNT study (Nord-Trøndelag Health Study) in Norway. Hypertension. 2017;69(4):591–8. https://doi.org/10.1161/HYPERTENSIONAHA.116.08414.; Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–736S. https://doi.org/10.1378/chest.11-2300.; Kelliher S., Maguire P.B., Szklanna P.B. et al. Pathophysiology of the venous thromboembolism risk in preeclampsia. Hamostaseologie. 2020;40(5):594–604. https://doi.org/10.1055/a-1162-3905.; Schaefer C., Hannemann D., Meister R. et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost. 2006;95(6):949–57. https://doi.org/10.1160/TH06-02-0108.; Mohzari Y.A., Asdaq S.M.B., Bamogaddam R.F. et al. Postpartum prophylaxis of venous thromboembolism with anticoagulation: a case report. J Taibah Univ Med Sci. 2021;16(2):292–4. https://doi.org/10.1016/j.jtumed.2020.12.016.; Sessa M., Mascolo A., Callreus T. et al. Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase®. Sci Rep. 2019;9(1):7236. https://doi.org/10.1038/s41598-019-43715-4.; Quinlan D.J., Mcquillan A., Eikelboom J.W. Low molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004;140(3):175–83. https://doi.org/10.7326/0003-4819-140-3-200402030-00008.; Galambosi P., Hiilesmaa V., Ulander V.M. et al. Prolonged low molecularweight heparin use during pregnancy and subsequent bone mineral density. Thromb Res. 2016;143:122–6. https://doi.org/10.1016/j.thromres.2016.05.016.; Bapat P., Pinto L.S., Lubetsky A. et al. Examining the transplacental passage of apixaban using the dually perfused human placenta. J Thromb Haemost. 2016;14(7):1436–41. https://doi.org/10.1111/jth.13353.; von Schmidt auf Altenstadt J.F., Hukkelhoven C.W.P.M., van Roosmalen J., Bloemenkamp K.W.M. Pre-eclampsia increases the risk of postpartum haemorrhage: a nationwide cohort study in the Netherlands. PLoS One. 2013;8(12):e81959. https://doi.org/10.1371/journal.pone.0081959.; Rodger M.A., Gris J.C., de Vries J.I.P. et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a metaanalysis of individual patient data from randomised controlled trials. Lancet. 2016;388(10060):2629–41. https://doi.org/10.1016/S0140-6736(16)31139-4.; Leduc D., Senikas V., Lalonde A.B., Clinical Practice Obstetrics Committee. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can. 2009;31:980–93. https://doi.org/10.1016/S1701-2163(16)34329-8.; Chan W.-S., Rey E., Kent N.E. et al. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527–53. https://doi.org/10.1016/s1701-2163(15)30569-7.; Bates S.M., Rajasekhar A., Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317–59. https://doi.org/10.1182/bloodadvances.2018024802.; Branch D.W., Holmgren C., Goldberg J.D. Committee on Practice Bulletins – Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: antiphospholipid antibody syndrome. Obstet Gynaecol. 2012;120(6):1514–21. https://doi.org/10.1097/01.AOG.0000423816.39542.0f.; https://www.gynecology.su/jour/article/view/1361
-
9Academic Journal
Authors: E. Grandone, Э. Грандоне
Source: Obstetrics, Gynecology and Reproduction; Vol 16, No 1 (2022); 90-95 ; Акушерство, Гинекология и Репродукция; Vol 16, No 1 (2022); 90-95 ; 2500-3194 ; 2313-7347
Subject Terms: НМГ, ART, in vitro fertilization, IVF, venous thromboembolism, VTE, pulmonary embolism, PE, low molecular weight heparins, LMWH, ВРТ, экстракорпоральное оплодотворение, ЭКО, венозная тромбоэмболия, ВТЭ, тромбоэмболия легочной артерии, ТЭЛА, низкомолекулярные гепарины
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1246/996; Mara M., Koryntova D., Rezabek K.et al. Thromboembolic complications in patients undergoing in vitro fertilization: retrospective clinical study. Ceska Gynekol. 2004;69(4):312–6. [Article in Czech].; Grandone E., Colaizzo D., Vergura P. et al. Age and homocysteine plasma levels are risk factors for thrombotic complications after ovarian stimulation. Hum Reprod. 2004;19(8):1796–9. https://doi.org/10.1093/humrep/deh346.; Chan W.S., Ginsberg J.S. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the ‘ART’ behind the clot. J Thromb Haemost. 2006;4(8):1673–7. https://doi.org/10.1111/j.1538-7836.2006.02026.x.; Chan W.S. The ‘ART’of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009;21(3):207–18. https://doi.org/10.1097/GCO.0b013e328329c2b8.; Chan W.S., Dixon M.E. The “ART” of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res. 2008;121(6):713–26. https://doi.org/10.1016/j.thromres.2007.05.023.; Piazza G. Oh heavy burden: recognizing the risk of venous thromboembolism in women undergoing assisted reproduction. Thromb Haemost. 2018;118(12):2011–3. https://doi.org/10.1055/s-0038-1676073.; Henriksson P., Westerlund E., Wallen H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:e8632. https://doi.org/10.1136/bmj.e8632.; Sennström M., Rova K., Hellgren M. et al. Thromboembolism and in vitro fertilization–a systematic review. Acta Obstet Gynecol Scand. 2017;96(9):1045–52. https://doi.org/10.1111/aogs.13147.; Marongiu F., Mameli A., Grandone E., Barcellona D. et al. Pulmonary thrombosis: a clinical pathological entity distinct from pulmonary embolism? Semin Thromb Hemost. 2019;45(8):778–83. https://doi.org/10.1055/s-0039-1696942.; Grandone E., Di Micco P.P., Villani M. et al. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE registry. Thromb Hemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.; Cantwell R., Clutton-Brock T., Cooper G. et al. Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006–-2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG. 2011;118 Suppl 1:1–203. https://doi.org/10.1111/j.1471-0528.2010.02847.x.; Braat D.D.M., Schutte J.M., Bernardus R.E. et al. Maternal death related to IVF in the Netherlands 1984–2008. Hum Reprod. 2010;25(7):1782–6. https://doi.org/10.1093/humrep/deq080.; Selter J., Huang Y., Becht L.C.G. et al. Use of fertility preservation services in female reproductive-aged cancer patients. Am J Obstet Gynecol. 2019;221(4):328.e1–328.e16. https://doi.org/10.1016/j.ajog.2019.05.009.; Rova K., Passmark H., Lindqvist P.G. et al. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012;97(1):95–100. https://doi.org/10.1016/j.fertnstert.2011.10.038.; Zore T., Joshi N.V., Lizneva D., Azziz R. Polycystic ovarian syndrome: long-term health consequences. Semin Reprod Med. 2017;35(3):271–81. https://doi.org/10.1055/s-0037-1603096.; Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–e736S. https://doi.org/10.1378/chest.11-2300.; Bates S.M., Rajasekhar A., Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317–59. https://doi.org/10.1182/bloodadvances.2018024802.; The Management of Ovarian Hyperstimulation Syndrome. Green-top Guideline No. 5. RCOG, 2016. 22 p. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_5_ohss.pdf.; Lindqvist P.G., Dahlbäck B. Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy. Thromb Haemost. 2000;84(7):140–1.; Galambosi P.J., Kaaja R.J., Stefanovi V., Ulander V.-M. et al. Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Biol. 2012;163(2):154–9. https://doi.org/10.1016/j.ejogrb.2012.05.010.; https://www.gynecology.su/jour/article/view/1246
-
10Academic Journal
Authors: А.П. Хрыкин, А.В. Орлов
Subject Terms: ультразвук, венозная тромбоэмболия, разрушение тромбов, волновод
Relation: https://zenodo.org/records/4459052; oai:zenodo.org:4459052; https://doi.org/10.5281/zenodo.4459052
-
11Academic Journal
Source: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 69 No. 1 (2021): Medical Sciences; 152-156 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 69 Nr. 1 (2021): Ştiinţe medicale; 152-156 ; Вестник Академии Наук Молдовы. Медицина; Том 69 № 1 (2021): Медицина; 152-156 ; 1857-0011 ; 10.52692/1857-0011.2021.1-69
Subject Terms: венозная тромбоэмболия, рак, шкала риска, тромбопрофилактик, venous thromboembolism, risc factor, thromboprophylaxis, tromboembolism venos, cancer, factori de risc, tromborofilaxie
File Description: application/pdf
Relation: https://bulmed.md/bulmed/article/view/3291/3291; https://bulmed.md/bulmed/article/view/3291
-
12Academic Journal
Source: Reproductive Endocrinology; No. 58 (2021); 9-16
Репродуктивная эндокринология; № 58 (2021); 9-16
Репродуктивна ендокринологія; № 58 (2021); 9-16Subject Terms: 03 medical and health sciences, 0302 clinical medicine, angiotensin-converting enzyme 2 receptors, менопаузальная гормональная терапия, комбинированные гормональные контрацептивы, венозная тромбоэмболия, combined hormonal contraceptives, venous thromboembolism, рецепторы ангиотензинпревращающего фермента 2, незарегистрированные рецептурные биоидентичные гормональные средства, 3. Good health, menopausal hormonal therapy, unregistered compounded bioidentical hormonal agents
File Description: application/pdf
Access URL: http://reproduct-endo.com/article/view/232680
-
13Academic Journal
-
14Academic Journal
Authors: Zhirova, N. V., Tutynina, O. V., Kiseleva, E. Ju., Жирова, Н. В., Тутынина, О. В., Каскаева, Д. С., Киселева, Е. Ю.
Subject Terms: PREGNANCY, VENOUS THROMBOEMBOLISM, ANTIPHOSPHOLIPID SYNDROME, THROMBOPHILIA, БЕРЕМЕННОСТЬ, ВЕНОЗНАЯ ТРОМБОЭМБОЛИЯ, АНТИФОСФОЛИПИДНЫЙ СИНДРОМ, ТРОМБОФИЛИЯ
File Description: application/pdf
Relation: Уральский медицинский журнал. 2020. № 1(184).; http://elib.usma.ru/handle/usma/18862
Availability: http://elib.usma.ru/handle/usma/18862
-
15Academic Journal
Authors: Sushinskaya T.V., Stuklov N.I., Dobrokhotova Yu.E.
Source: Онкология. Журнал им. П.А. Герцена
Subject Terms: hemostatic disease, патология гемостаза, cancer, venous thromboembolism, pulmonary embolism, diagnosis, prevention, Low-molecular-weight heparins, treatment, рак, венозная тромбоэмболия, тромбоэмболия легочной артерии, диагностика, профилактика, низкомолекулярные гепарины, лечение
Availability: https://openrepository.ru/article?id=245000
-
16Academic Journal
Authors: TZORAN INNA, BRENNER BENJAMIN
Source: Акушерство, гинекология и репродукция, Vol 10, Iss 1, Pp 11-25 (2016)
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, anticoagulant therapy, venous thromboembolism, RG1-991, Gynecology and obstetrics, DIRECT ORAL ANTICOAGULANTS,VENOUS THROMBOEMBOLISM,ANTICOAGULANT THERAPY,ОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ ПРЯМОГО ДЕЙСТВИЯ,ВЕНОЗНАЯ ТРОМБОЭМБОЛИЯ,АНТИКОАГУЛЯНТНАЯ ТЕРАПИЯ, direct oral anticoagulants, 3. Good health
File Description: text/html
Access URL: https://doaj.org/article/72e0cae95d5e4647a25c384320f53251
http://akusherstvo.elpub.ru/jour/article/view/32
https://www.gynecology.su/jour/article/view/32
https://cyberleninka.ru/article/n/direct-oral-anticoagulants/pdf
https://www.gynecology.su/jour/article/download/32/522
https://cyberleninka.ru/article/n/direct-oral-anticoagulants
http://cyberleninka.ru/article/n/direct-oral-anticoagulants
http://cyberleninka.ru/article_covers/16792244.png -
17
-
18Academic Journal
Authors: I. Elalamy, И. Элалами
Source: Obstetrics, Gynecology and Reproduction; Vol 13, No 3 (2019); 245-254 ; Акушерство, Гинекология и Репродукция; Vol 13, No 3 (2019); 245-254 ; 2500-3194 ; 2313-7347
Subject Terms: мутация Лейдена, deep vein thrombosis, pulmonary embolism, venous thromboembolism, thrombosis, Leiden mutation, тромбоз глубоких вен, тромбоэмболия легочной артерии, венозная тромбоэмболия, тромбоз
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/578/754; https://www.gynecology.su/jour/article/view/578/755; Scheres J.J., Lijfering W.M., Cannegieter S.C. Current and future burden of venous thrombosis: Not simply predictable. Res Pract Thromb Haemost. 2018;2(2):199–208. DOI:10.1002/rth2.12101.; Wendelboe A.M., Raskob G.E. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340–7. DOI:10.1161/CIRCRESAHA.115.306841.; Bouée S., Emery C., Samson A. et al. Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database. Thromb J. 2016;14(1):4. DOI:10.1186/s12959-016-0078-0.; Burwen D.R., Wu C., Cirillo D. et al. Venous thromboembolism incidence, recurrence, and mortality based on Women's Health Initiative data and Medicare claims. Thromb Res. 2017;150:78–85. DOI:10.1016/j.thromres.2016.11.015.; Cohen A.T., Agnelli G., Anderson F.A. et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007;98(4):756–64.; Byrnes J.R., Wolberg A.S. New findings on venous thrombogenesis. Hämostaseologie. 2017;37(1):25–35. DOI:10.5482/HAMO-16-09-0034.; Di Nisio M., van Es N., Büller H.R. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060–73. DOI:10.1016/S0140-6736(16)30514-1.; Conti E., Zezza L., Ralli E. et al. Pulmonary embolism in pregnancy. J Thromb Thrombolysis. 2014;37(3):251–70. DOI:10.1007/s11239-013-0941-9.; Fuchs T.A., Brill A., Wagner D.D. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012;32(8):1777–83. DOI:10.1161/ATVBAHA.111.242859.; Gould T.J., Lysov Z., Liaw P.C. Extracellular DNA and histones: double-edged swords in immunothrombosis. J Thromb Haemost. 2015;13(Suppl 1):S82–S91. DOI:10.1111/jth.12977.; Giaglis S., Stoikou M., Sur Chowdhury C. et al. Multimodal regulation of NET formation in pregnancy: progesterone antagonizes the pro-NETotic effect of estrogen and G-CSF. Front Immunol. 2016;7:565. DOI:10.3389/fimmu.2016.00565.; Takagi Y., Murata M., Kozuka T. et al. Missense mutations in the gene encoding prothrombin corresponding to Arg596 cause antithrombin resistance and thrombomodulin resistance. Thromb Haemost. 2016;116(6):1022–31. DOI:10.1160/TH16-03-0223.; Wang T.F., Li A., Garcia D. Managing thrombosis in cancer patients. Res Pract Thromb Haemost. 2018;2(3):429–38. DOI:10.1002/rth2.12102.; Zöller B., Hillarp A., Dahlbäck B. State-of-the-Art Review: activated protein C resistance: clinical implications. Clin Appl Thromb Hemost. 1997;3(1):25–32.; Naess I.A., Christiansen S.C., Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–9. DOI:10.1111/j.1538-7836.2007.02450.x.; Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e691S–e736S. DOI:10.1378/chest.11-2300.; Austin A.W, Wissmann T., von Kanel R. Stress and hemostasis: an update. Semin Thromb Hemost. 2013;39(8):902–12. DOI:10.1055/s-0033-1357487.; Bentur O.S., Sarig G., Brenner B., Jacob G. Effects of acute stress on thrombosis. Semin Thromb Hemost. 2018;44(7):662–8. DOI:10.1055/s-0038-1660853.; Lijfering W.M., Flinterman L.E., Vandenbroucke J.P. et al. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost. 2011;37(8):885–96. DOI:10.1055/s-0031-1297367.; Holst A.G., Jensen G., Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation. 2010;121(17):1896–903. DOI:10.1161/CIRCULATIONAHA.109.921460.; Monreal M., Mahé I., Bura-Riviere A. et al. Pulmonary embolism: Epidemiology and registries. Presse Med. 2015;44(12 Pt 2):e377–e383. DOI:10.1016/j.lpm.2015.10.006.; Bikdeli B., Jimenez D., Hawkins M. et al. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost. 2018;118(1):214–24. DOI:10.1160/TH17-07-0511.; Wendelboe A.M., McCumber M., Hylek E.M. et al. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015;13:1365–71. DOI:10.1111/jth.13031.; https://www.gynecology.su/jour/article/view/578
-
19Academic Journal
Authors: A. D. Makatsariya, V. O. Bitsadze, D. V. Blinov, D. I. Korabelnikov, А. Д. Макацария, В. О. Бицадзе, Д. В. Блинов, Д. И. Корабельников
Source: Obstetrics, Gynecology and Reproduction; Vol 13, No 1 (2019); 7-12 ; Акушерство, Гинекология и Репродукция; Vol 13, No 1 (2019); 7-12 ; 2500-3194 ; 2313-7347
Subject Terms: риск, intestinal and urinary microbiomes, somatic diseases, диеногест, этинилэстрадиол, фиксированная комбинация, комбинированные гормональные контрацептивы, комбинированные оральные контрацептивы, венозная тромбоэмболия
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/547/726; О новых данных по безопасности комбинированных гормональных контрацептивов (КГК). Информационное письмо № 01И-778/19 от 20.03.2019. Федеральная Служба по Надзору в Сфере Здравоохранения (Росздравнадзор). Режим доступа: http://www.roszdravnadzor.ru/spec/drugs/monitpringlp/documents/58397. [Дата доступа: 22.03.2019].; Dinger J., Assmann A., Mohner S., Minh T.D. Risk of venous thrombo-embolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann ReprodHealth Care. 2010;36:1239. DOI:10.1783/147118910791749416.; Dinger J.C., Heinemann L.A., Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75(5):344-54.; Бышевский А.Ш., Полякова В.А., Карпова И.А. и соавт. Гемокоагуляция и липидпероксидация у женщин, принимавших половые стероиды с этинилэстрадиолом и прогестагенами. ВестникЮУрГУ. 2012;(28):58-62.; Dienogest/ethinyl estradiol containing medicinal products indicated in acne. Assessment report, European Medicines Agency. EMA/174401/201. Режим доступа: https://www.ema.europa.eu/en/medicines/human/referrals/dienogestethinylestradiol-containing-medicinal-products-indicated-acne. [Дата доступа: 22.03.2019].; Жанин. Инструкция по медицинскому применению. П N013757/01. Режим доступа: http://www.grls.rosminzdrav.ru. [Дата доступа: 22.03.2019].; Диеногест + Этинилэстрадиол. Инструкция по медицинскому применению. ЛП-004470. Режим доступа: http://www.grls.rosminzdrav.ru. [Дата доступа: 22.03.2019].; Фемисс Месси. Инструкция по медицинскому применению. ЛП-004011. Режим доступа: http://www.grls.rosminzdrav.ru. [Дата доступа: 22.03.2019].; Бонадэ. Инструкция по медицинскому применению. ЛП-002523. Режим доступа: http://www.grls.rosminzdrav.ru. [Дата доступа: 22.03.2019].; Диециклен. Инструкция по медицинскому применению. ЛП-001494. Режим доступа: http://www.grls.rosminzdrav.ru. [Дата доступа: 22.03.2019].; Силует. Инструкция по медицинскому применению. ЛП-001145. Режим доступа: http://www.grls.rosminzdrav.ru. [Дата доступа: 22.03.2019].; https://www.gynecology.su/jour/article/view/547
-
20Academic Journal
Authors: G. A. Ignatenko, G. G. Taradin, N. T. Vatutin, I. V. Kanisheva, Г. А. Игнатенко, Г. Г. Тарадин, Н. Т. Ватутин, И. В. Канишева
Source: The Russian Archives of Internal Medicine; Том 9, № 5 (2019); 348-366 ; Архивъ внутренней медицины; Том 9, № 5 (2019); 348-366 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2019-0-5
Subject Terms: геморрагические осложнения, venous thromboembolism, thromboembolism of pulmonary artery, treatment, risk stratification, anticoagulant therapy, direct oral anticoagulants, systemic thrombolysis, fibrinolysis, bleeding complications, венозная тромбоэмболия, тромбоэмболия легочной артерии, лечение, стратификация риска, антикоагулянтная терапия, прямые оральные антикоагулянты, системный тромболизис, фибринолиз
File Description: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/963/835; https://www.medarhive.ru/jour/article/view/963/842; Konstantinides S.V., Torbicki A., Agnelli G., et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) endorsed by the european respiratory society (ERS). European Heart Journal. 2014; 35(43): 3033–69, 3069a-3069k. DOI:10.1093/eurheartj/ehu283.; Tritschler T, Kraaijpoel N, Le Gal G, Wells PS. Venous thromboembolism: advances in diagnosis and treatment. JAMA. 2018 Oct 16;320(15):1583-1594. doi:10.1001/jama.2018.14346.; Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;126(9): 832.e13-832. doi:10.1016/j.amjmed.2013.02.024; Konstantinides S.V., Barco S., Lankeit M., Meyer G. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90. doi:10.1016/j.jacc.2015.11.061.; Carrier M, Righini M, Wells PS, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications: a systematic review and meta-analysis of the management outcome studies. J Thromb Haemost. 2010;8(8):1716-1722. doi:10.1111/j.1538-7836.2010.03938.x; Ватутин Н.Т., Тарадин Г.Г., Канишева И.В. и др. Роль интервенционных методов в лечении острой легочной эмболии. Архивъ внутренней медицины. 2018; 8(5):346-360. doi:10.20514/22266704-2018-0-5-346-360.; Torbicki A, Perrier A, Konstantinides S, et al.; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008 Sep;29(18):2276-315. doi:10.1093/eurheartj/ehn310.; Jaff M.R., McMurtry M.S., Archer S.L., et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a Scientific Statement from the American Heart Association. Circulation 2011;123(16):1788-830. doi:10.1161/CIR.0b013e318214914f.; Sekhri V, Mehta N, Rawat N, et al. Management of massive and nonmassive pulmonary embolism. Arch Med Sci. 2012 Dec 20; 8(6):957-69. doi:10.5114/aoms.2012.32402.; Bĕlohlavek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013 Spring;18(2):129-38.; Corrigan D, Prucnal C, Kabrhel C. Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients. Clin Exp Emerg Med. 2016 Sep; 3(3): 117–125. doi:10.15441/ceem.16.146; Miller G.A., Sutton G.C., Kerr I.H., et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J. 1971;2:681– 684.; Aujesky D., Obrosky D.S., Stone R.A., et al. Derivation and validation of a prognostic model for pulmonary embolism. Am. J. Respir. Crit. Care Med. 2005;172: 1041–1046.; Jimenez D, Aujesky D, Moores L, et al.; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010 Aug 9;170(15):1383-9. doi:10.1001/archinternmed.2010.199; Huisman M.V., Barco S., Cannegieter S.C., et al. Pulmonary embolism. Nat. Rev. Dis. Primers. 2018 May 17;4:18028. doi:10.1038/nrdp.2018.28.; Kabrhel C., Jaff M.R., Channick R.N., et al. A multidisciplinary pulmonary embolism response team. CHEST Journal. 2013; 144(5):1738-1739.; Root C.W., Dudzinski D.M., Zakhary B., et al. Multidisciplinary approach to the management of pulmonary embolism patients: the pulmonary embolism response team (PERT). J Multidiscip Healthc. 2018 Apr 5;11:187-195. doi:10.2147/JMDH.S151196.; Petriş AO, Konstantinides S, Tint D, et al. Therapeutic advances in emergency cardiology: acute pulmonary embolism. Am J Ther. 2019 Mar/Apr;26(2):e248-e256. doi:10.1097/MJT.0000000000000917.; Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. Lancet 1960;275(7138):1309–12.; Jolly M., Phillips J. Pulmonary embolism: current role of catheter treatment options and operative thrombectomy. Surg. Clin. North. Am. 2018 Apr;98(2):279-292. doi:10.1016/j.suc.2017.11.009.; Chopard R, Andarelli JN, Humbert S, et al. Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry. Thromb Res. 2019 Feb;174:27-33. doi:10.1016/j.thromres.2018.12.013.; Stein PD, Dalen JE, Matta F, et al. Optimal therapy for unstable pulmonary embolism. Am J Med. 2019 Feb;132(2):168-171. doi:10.1016/j.amjmed.2018.09.018.; Borohovitz A, Weinberg MD, Weinberg I. Pulmonary embolism: Care standards in 2018. Prog Cardiovasc Dis. 2018 Mar — Apr;60(6):613621. doi:10.1016/j.pcad.2017.12.005.; Hepburn-Brown M, Darvall J, Hammerschlag G. Acute pulmonary embolism: a concise review of diagnosis and management. Intern Med J. 2019 Jan;49(1):15-27. doi:10.1111/imj.14145; Kearon C, AgenoW, Cannegieter SC, et al.; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480-1483. doi:10.1111/jth.13336; Carrier M., Le G.G., Wells P.S., et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann. Intern. Med. 2010 May 4;152(9):578-89. doi:10.7326/0003-4819-152-9201005040-00008.; Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 Nov 27;2(22):3257-3291. doi:10.1182/bloodadvances.2018024893.; Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026.; Heidbuchel H., Verhamme P., Alings M., et al. EHRA practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation: executive summary. Eur Heart J. 2013 Jul; 34(27): 20942106. doi:10.1093/eurheartj/eht134.; Beyer-Westendorf J., Verhamme P., Bauersachs R. Betrixaban for prevention of venous thromboembolism in acute medically ill patients. Eur Heart J Suppl. 2018 May;20(Suppl E):E16-E22. doi:10.1093/eurheartj/suy017; van Es N., Coppens M., Schulman S., et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; Sep 18; 124(12):1968-75. doi:10.1182/blood-2014-04-571232.; van der Hulle T., Kooiman J., den Exter P.L., et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J. Thromb. Haemost. 2014;12(3):320-8. doi:10.1111/jth.12485.; Arcadi FA, Portaro S, Giorgianni R, et al. New versus old oral anticoagulants: how can we set the scale needle? Considerations on a case report. Medicina (Kaunas). 2019 Mar 17;55(3). pii: E71. doi:10.3390/medicina55030071; Dawwas GK, Brown J, Dietrich E, et al. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol. 2019 Jan;6(1):e20-e28. doi:10.1016/S23523026(18)30191-1.; Schulman S., Kearon C., Kakkar A.K., et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52. doi:10.1056/NEJMoa0906598.; Schulman S., Kakkar A.K., Goldhaber S.Z., et al.; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-72. doi:10.1161/CIRCULATIONAHA.113.004450; Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510. doi:10.1056/NEJMoa1007903.; Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. doi:10.1056/NEJMoa1113572; Agnelli G., Buller H.R., Cohen A., et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. doi:10.1056/NEJMoa1302507.; Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15. doi:10.1056/NEJMoa1306638.; Martin K., Beyer-Westendorf J., Davidson B.L., et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J. Thromb. Haemost. 2016 Jun;14(6):1308-13. doi:10.1111/jth.13323.; Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133(5):425-435. doi:10.1182/blood-2018-06-820746; Shakur H, Roberts I, Bautista R, et al.; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376(9734):23-32. doi:10.1016/S0140-6736(10)60835-5.; Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost. 2017 Apr;43(3):277-290. doi:10.1055/s-0036-1597296; Mosarla RC, Vaduganathan M, Qamar A, et al. Anticoagulation strategies in patients with cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 Mar 26;73(11):1336-1349. doi:10.1016/j.jacc.2019.01.017; Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10; 349(2):146-53.; Lee AYY, Kamphuisen PW, Meyer G, et al.; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015 Aug 18;314(7):677-686. doi:10.1001/jama.2015.9243.; Raskob GE, van Es N, Verhamme P, et al.; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378:615–24. doi:10.1056/NEJMoa1711948; Young A, Marshall A, Thirlwall J, et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D Pilot Trial. Blood 2017; 130:625.; Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res 2018: doi:10.1016/j.thromres.2018.02.144.; Peacock WF, Singer AJ. Reducing the hospital burden associated with the treatment of pulmonary embolism. J Thromb Haemost. 2019 Mar 9. doi:10.1111/jth.14423; Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018 Sep;16(9):1891-1894. doi:10.1111/jth.14219.; Bartel B. Systemic thrombolysis for acute pulmonary embolism. Hosp. Pract. 2015;43(1):22-7. doi:10.1080/21548331.2015.1001302.; Konstantinides S.V., Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin. Respir. Crit. Care Med. 2017 Feb;38(1):56-65. doi:10.1055/s-0036-1597560.; Marti C., John G., Konstantinides S., et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2015; 36(10):605-14. doi:10.1093/eurheartj/ehu218.; Stein P.D., Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med. 2012; 125(5):465-70. doi:10.1016/j.amjmed.2011.10.015.; Murphy E, Lababidi A, Reddy R, et al. The role of thrombolytic therapy for patients with a submassive pulmonary embolism. Cureus. 2018;10(6):e2814. doi:10.7759/cureus.2814; Virk HUH, Chatterjee S, Sardar P, et al. Systemic thrombolysis for pulmonary embolism: evidence, patient selection, and protocols for management. Interv Cardiol Clin. 2018 Jan;7(1):71-80. doi:10.1016/j.iccl.2017.08.001.; Никитина О.В., Михайлов И.П., Кудряшова Н.Е. и др. Тромболитическая и антикоагулянтная терапия при тромбоэмболии легочной артерии: влияние на легочную перфузию (часть 2). Журнал им. Н.В. Склифосовского Неотложная медицинская помощь. 2018; 7(2): 134–143. DOI:10.23934/2223-9022-2018-7-2-134-143.; Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125(3):e82–e86. doi:10.1016/j.thromres.2009.09.017; Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2(3):227-229.; Kline J.A., Steuerwald M.T., Marchick M.R., et al. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009;136:1202-10.; Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18; 311(23):2414-21. doi:10.1001/jama.2014.5990; Bougouin W., Marijon E., Planquette B., et al.; on behalf from the Sudden Death Expertise Center. Pulmonary embolism related sudden cardiac arrest admitted alive at hospital: Management and outcomes. Resuscitation. 2017;115:135-140. doi:10.1016/j.resuscitation.2017.04.019.; Zuin M, Rigatelli G, Carraro M, et al. Systemic thrombolysis in haemodynamically unstable pulmonary embolism: The earlier the better? Thromb Res. 2019 Jan;173:117-123. doi:10.1016/j.thromres.2018.11.029.; Fernandes CJCDS, Jardim CVP, Alves JL Jr, et al. Reperfusion in acute pulmonary thromboembolism. J Bras Pneumol. 2018 Jun 7:0. doi:10.1590/S1806-37562017000000204.; Becattini C., Agnelli G., Lankeit M., et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur. Respir. J. 2016;48(3):780-6. doi:10.1183/13993003.00024-2016.; Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014 Apr;12(4):459-68. doi:10.1111/jth.12521.; Konstantinides S., Geibel A., Heusel G., et al.; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002 Oct 10; 347(15):1143-50.; Sharifi M., Bay C., Skrocki L., et al.; “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol. 2013;111(2):273-7. doi:10.1016/j.amjcard.2012.09.027.; Riva N., Puljak L., Moja L., et al. Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism. J Clin Epidemiol. 2018;97:1-13. doi:10.1016/j.jclinepi.2017.11.012.; Teleb M, Porres-Aguilar M, Anaya-Ayala JE, et al. Potential role of systemic thrombolysis in acute submassive intermediate risk pulmonary embolism: review and future perspectives. Ther Adv Cardiovasc Dis. 2016;10(2):103–110. doi:10.1177/1753944716630694; Meyer G., Vicaut E., Danays T., et al.; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370(15):1402-11. doi:10.1056/NEJMoa1302097.; Miranda CH. Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. J Bras Pneumol. 2019 Feb 11;45(1):e20180297. doi:10.1590/1806-3713/e20180297.; Klok F.A., Dzikowska-Diduch O., Kostrubiec M., et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J. Thromb. Haemost. 2016;14(1):121-8. doi:10.1111/jth.13175; Goldhaber S.Z. PEITHO Long-Term Outcomes Study: Data Disrupt Dogma. J Am Coll Cardiol. 2017 Mar 28;69(12):1545-1548. doi:10.1016/j.jacc.2017.01.027.; Konstantinides S.V., Vicaut E., Danays T., et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol. 2017;69(12):1536-1544. doi:10.1016/j.jacc.2016.12.039.; Jimenez D, de Miguel-Diez J, Guijarro R, et al; RIETE Investigators. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE Registry. J Am Coll Cardiol. 2016;67(2):162–170 doi:10.1016/j.jacc.2015.10.060.; Wang C, Zhai Z, Yang Y, et al.; China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010; Feb;137(2):254-62. doi:10.1378/chest.09-0765.; Kiser TH, Burnham EL, Clark B, et al. Half-dose versus full-dose alteplase for treatment of pulmonary embolism. Crit Care Med. 2018 Oct;46(10):1617-1625. doi:10.1097/CCM.0000000000003288.; Jin Q, Luo Q, Zhao Z, et al. Half-dose versus full-dose alteplase therapy in pulmonary embolism: does half dose really lose? Crit Care Med. 2018 Dec;46(12):e1223-e1224. doi:10.1097/CCM.0000000000003384; Rothschild DP, Goldstein JA, Bowers TR. Low-dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: Clinical efficacy but attendant hemorrhagic risks. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):506-510. doi:10.1002/ccd.28042.; Halaby R, Giri J. Keep it simple? Half-dose systemic thrombolysis or catheter-directed thrombolysis for pulmonary embolism. Vasc Med. 2019 Mar 5:1358863X18824653. doi:10.1177/1358863X18824653.; https://www.medarhive.ru/jour/article/view/963
